President Donald Trump announced a groundbreaking deal with Eli Lilly and Novo Nordisk on November 6, 2025, to dramatically cut prices for popular obesity and diabetes medications.
The Deal at a Glance
Under the new TrumpRx program, Americans will see steep discounts on blockbuster GLP-1 drugs:
- Injectable medications (Wegovy, Ozempic, Zepbound): Starting at $350/month, dropping to $245/month over two years—down from current prices of $1,000-1,350
- Oral versions (pending FDA approval): As low as $145/month
- Medicare copay: Just $50 for eligible patients
“For too long, Americans have been paying the highest prices in the world for life-changing drugs,” Trump said at the White House announcement. “This deal brings real savings to real people.”
What’s Changing
The agreement marks a major policy shift. For the first time, Medicare will cover obesity treatment medications, ending years of exclusion. Medicaid expansion is also planned, with states expected to follow suit.
The TrumpRx platform will launch as a direct-to-consumer website in January 2026, initially serving specific patient groups before expanding to broader eligibility.
Market Impact
The announcement sent shares of both pharmaceutical giants fluctuating as investors weighed reduced profit margins against potential growth from wider market access.
Healthcare economists warn that surging demand could strain already-stretched supply chains.
“The impact will be felt far beyond the U.S.,” noted one analyst. “Cheaper access in America could shift export priorities, affecting pricing negotiations worldwide.”
The Bottom Line
If fully implemented, this deal could reshape how obesity and diabetes medications are priced globally—potentially bringing relief to millions while testing the limits of pharmaceutical manufacturing and distribution networks.
Also Read
Stock Market Dow Jones Today: Tech Turbulence Shakes Wall Street
Datadog Sees Shares Climb Nearly 4% on Exceptional Third-Quarter Performance
